SCHEMBL1014280

SCHEMBL1014280

CON(C)C(=O)c1ccc(CN2CCOCC2)c(C)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A13 Q16696 1/20 0.47
MAPT P10636 3/20 0.44
KDM4E B2RXH2 2/20 0.44
ALDH1A1 P00352 2/20 0.44
LMNA P02545 1/20 0.44
RECQL P46063 1/20 0.44
CYP2C9 P11712 1/20 0.43
ALOX15 P16050 1/20 0.43
HSD17B10 Q99714 1/20 0.43
POLB P06746 1/20 0.43
HCRTR1 O43613 1/20 0.42
HCRTR2 O43614 1/20 0.42
HIF1A Q16665 1/20 0.42
EPAS1 Q99814 1/20 0.42
KMT2A Q03164 3/20 0.42
CNR2 P34972 2/20 0.42
MEN1 O00255 1/20 0.41
HTT P42858 1/20 0.41
JAK2 O60674 1/20 0.41
JAK1 P23458 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1014530 0.87 MAPT (0.51) MAPTKDM4EALDH1A1LMNARECQL
SCHEMBL1421404 0.86 CTSB (0.50) MAPTKDM4EALDH1A1LMNARECQL
SCHEMBL1014491 0.81 HIF1A (0.61) KDM4ELMNAHIF1AEPAS1KMT2A
SCHEMBL1011690 0.81 CYP2A13 (0.55) CYP2A13MAPTKDM4EALDH1A1CYP2C9
SCHEMBL4262164 0.80 CYP2A13 (0.54) CYP2A13MAPTKDM4EALDH1A1CYP2C9
SCHEMBL1014092 0.80 ABL1 (0.50) KDM4EALDH1A1LMNACYP2C9HIF1A
SCHEMBL27828920 0.79 CYP2A13 (0.52) CYP2A13MAPTKDM4EALDH1A1CYP2C9
SCHEMBL1011847 0.79 MCHR1 (0.48) KDM4ELMNAHIF1AEPAS1KMT2A
SCHEMBL20496747 0.73 MAPK1 (0.55) CYP2A13ALDH1A1ALOX15HSD17B10POLB
SCHEMBL25062364 0.72 GSK3B (0.51) MAPTKDM4EALDH1A1LMNARECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110034466-A1 NOVEL FIVE-MEMBERED RING COMPOUND DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-02-10 US disclosed
US-20110034466-A1 NOVEL FIVE-MEMBERED RING COMPOUND DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-02-10 US disclosed
US-20110034466-A1 NOVEL FIVE-MEMBERED RING COMPOUND DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-02-10 US disclosed
EP-2272835-A1 NOVEL FIVE-MEMBERED RING COMPOUND Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-01-12 EP disclosed
WO-2009131171-A1 NOVEL FIVE-MEMBERED RING COMPOUND 大日本住友製薬株式会社 (JP) 2009-10-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110034466-A1 NOVEL FIVE-MEMBERED RING COMPOUND CCL11, CCR1, CCR10 CYP2A13 929/4885MAPT 4799/4885KDM4E 2508/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.